Download Free Medical Narcotic Withdrawal Syndrome Neonatal Abstinence Syndrome PowerPoint Presentation

Narcotic Withdrawal Syndrome Neonatal Abstinence Syndrome PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Narcotic Withdrawal Syndrome Neonatal Abstinence Syndrome” by Henrietta S. Bada, MD, MPH.

This medical PowerPoint presentation is about Narcotic withdrawal syndrome, also known as neonatal abstinence syndrome (NAS). Neonatal abstinence syndrome is a condition that occurs in newborns who have been exposed to addictive substances, such as opioids, during pregnancy.

When a pregnant woman uses opioids or other addictive substances, these drugs can cross the placenta and enter the babys bloodstream. The baby becomes dependent on the drug and experiences withdrawal symptoms after birth when the drug is no longer available.

Symptoms of NAS can include irritability, high-pitched crying, tremors, seizures, vomiting, diarrhea, sweating, fever, and poor feeding. These symptoms can vary in severity depending on the type of drug used, the amount used, and the length of time the baby was exposed to the drug in utero.

Treatment for NAS may include medication to ease withdrawal symptoms, such as methadone or morphine, and supportive care, such as providing a quiet and dark environment, swaddling the baby, and offering small, frequent feedings.

It is important for pregnant women who are using opioids or other addictive substances to seek medical help to manage their addiction and reduce the risk of NAS in their babies.

Tags : Narcotic Withdrawal Syndrome, Neonatal Abstinence Syndrome, Neonatal-Perinatal Medicine, Neonatal-Perinatal Medicine PowerPoint presentation

Published on : Jun 07, 2023 | Views : 747 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Narcotic Withdrawal SyndromeNeonatal Abstinence Syndrome Henrietta S. Bada, MD, MPH Mary Florence Jones Professor of Pediatrics Chief, Division of Neonatology University of Kentucky
Slide 2-

Public Health Perspective Substance abuse: Public Health Problem and Social Morbidity NSDUH (National Survey on Drug Use and Health) 2007/2008 estimates Annual Rates Rates Est. Births Drugs Women (15-44y) Pregnancy Affected (2008) Illicit drugs 9.6% 5.1% 201,806 Tobacco 28.1% 16.7% 709,933 Alcohol 52.1% 10.6% 450,616
Slide 3-

Outline Scope of the problem of drug use in pregnancy Common drugs of abuse Approaches or methods for detection of drug exposure Signs of narcotic abstinence syndrome or drug withdrawal Goals in the approach to management of neonatal drug withdrawal Considerations in the pharmacologic treatment of narcotic abstinence syndrome Other issues in maternal-child interaction, including breastfeeding
Slide 4-

Public Health Perspective Substance abuse: Public Health Problem Social Morbidity NSDUH (National Survey on Drug Use and Health) 2007/2008 estimates Illegal Annual Rates Rates Est. Births Drugs Women (15-44y) Pregnancy Affected (2008) Illicit drugs 9.6% 5.1% 201,806 Marijuana 7.0% 3.8% 161,541 Cocaine 0.8% 0.4% 17,004 Pain relievers* 2.6% 0.7% 29,758 *1.6 million
Slide 5-

Drugs of Use or Abuse During Pregnancy Major Drugs of Abuse: Opioids: Agonists Antagonists Mixed agonist-antagonists Semi-synthetic opioids CNS stimulants Amphetamines Methamphetamines Cocaine Methylphenidate (Ritalin)
Slide 6-

Drugs of Use or Abuse During Pregnancy Major Drugs of Abuse: CNS depressants Alcohol Barbiturates Benzodiazepines Cannabinoids (marijuana, hashish) Other sedative-hypnotics Methaqualone (Quaalude) Ethchlorvynol (Placidyl) Glutethimide (Doriden) Methyprylon (Noludar) Ethinamate (Valmid) Chloral hydrate
Slide 7-

Drugs of Use or Abuse During Pregnancy Major Drugs of Abuse: Hallucinogens LSD Phenylethylamine (mescaline) Phenylisopropylamines (MDA, MMDA, MDEA, MDMA or 3,4-methyl-enedioxymethamphetamine or ecstasy) Inhalants Solvents and aerosols (glues, gasoline, paint thinner, cleaning solutions, nail polish remover, Freon) Nitrites Nitrous oxide
Slide 8-

Lexington Herald-Leader Source: Drug Enforcement Administration
Slide 9-

Lexington Herald-Leader Source: Drug Enforcement Administration
Slide 10-

Drugs of Use or Abuse During Pregnancy Semi-synthetic opioids (Oyxcodone) M-Oxy® OxyContin® OxyFast® OxyIR® Percolone® Roxicodone® OxyDose™ OxyNorm™ OxyRapid™ Roxicodone® Intensol Endocet® Percocet® Roxicet® Roxilox™ Tylox® Taxadone™
Slide 11-

Drugs of Use or Abuse During Pregnancy Semi-synthetic opioids (Hydrocodone) Anexsia®, Bancap™ HC, Ceta-Plus™, Co-Gesic®, Dolacet™, Dolagesic™, Dolorex™ Forte, Duocet™, Hy-Phen®, Hydrocet®, Hydrogesic™, Lorcet®, Lorcet-HD, Lorcet® Plus, Lortab®, Margesic-H™, Norco®, Panacet™, Polygesic™, Stagesic®, T-Gesic™, Ugesic™, Vanacet™, Vicodin®, Vicodin® ES, Vicodin®HP, Zydone® Allay™ Anolor® Dynol™ Hyco Pap™ Maxidone™ Procet® Vidone™
Slide 12-

Issues In Management of Infants Born to Substance Using Mothers Detection of drug use Variation in Manifestations (Term versus Preterm) Monitoring manifestations (withdrawal versus drug effects) Scoring system or scale The scores as basis to initiate therapy
Slide 13-

Detection of Drug Exposure Maternal Screening Admits to drug use Urine screening during pregnancy Maternal hair analysis Neonatal Screening Baby urine drug screen Meconium drug screen Baby hair analysis Umbilical cord analysis
Slide 14-

Detection of Drug Exposure Unreliability of history Urine and or meconium screening may be negative in the presence of in-utero exposure Negative neonatal urine if maternal use greater than 2 days before delivery Negative meconium if maternal use before 20 weeks gestational age
Slide 15-

Detection of Drug Exposure Diagnosis: History Suspicion based on risk factors Gravida > 3 No or late prenatal care Child or children not living with mother Other CPS involvement Abruptio placentae/ Placenta previa Physical injuries (ER visits) History of pain, headaches, migraine, etc STD’s, Risky lifestyles Disorientation, expression during interviews
Slide 16-

Prevalence of Use Among Drug Using Pregnant Women (%)
Slide 17-

Opiate & Polydrug Use In Rural Population (n=183)
Slide 18-

Detection of Drug Exposure Diagnosis: Urine drug screen Meconium drug screen: Need expanded opiate screen if looking for oxycodone, propoxyphene (Darvon) and methadone Need to also add Buprenorphine+/-Naloxone
Slide 19-

Drug Exposure Screening at UK: By history and infant testing
Slide 20-

Drug Exposure: Preterm versus Term Preterm infants may exhibit later and less severe symptoms Less immature CNS Shorter duration of exposure Scores of withdrawal may be related to prematurity (e.g. respiratory signs, poor feeding, etc)
Slide 21-

Withdrawal Versus Drug Effects CNS manifestations such as hypertonia, irritability, shrill cry, myoclonic jerks, seizures, especially in opiate exposure These manifestations may be noted with withdrawal Opiates, cocaine, and other drugs have also been demonstrated to affect brain development (prominent feature small head circumference).
Slide 22-

Perinatal Opiate Exposure Brain Infarct Term, uneventful delivery Transferred to Tertiary Center because of seizures ? Perinatal Depression: MRI: Stroke/infarct Negative work-up for perinatal stroke Clotting factors, Protein C and S, Anti-thrombin III and Anti-phospholipid levels were all within normal limits Negative for TORCH
Slide 23-

Withdrawal Versus Drug Effects CNS manifestations such as hypertonia, irritability, shrill cry, myoclonic jerks, seizures, especially in opiate exposure These manifestations may be noted with withdrawal Opiates, cocaine, and other drugs have also been demonstrated to affect brain development (prominent feature small head circumference).
Slide 24-

R R R L L1: L R R R L L
Slide 25-

Signs of Neonatal Narcotic Withdrawal Central Nervous System Signs High-pitched cry Decreased sleeping time Hyperactivity Hyper-reflexia Tremors Hypertonia Myoclonic jerks Convulsions Irritability
Slide 26-

Signs of Neonatal Narcotic Withdrawal Gastrointestinal disturbances Excessive sucking Poor feeding Regurgitation Projectile vomiting Loose to watery stools Metabolic/vaso-motor disturbances Sweating Fever Yawning Mottling
Slide 27-

Signs of Neonatal Narcotic Withdrawal Respiratory disturbances Nasal stuffiness Sneezing Nasal flaring Tachypnea Retractions
Slide 28-

Signs of Neonatal Narcotic Withdrawal Other manifestations Abrasions or excoriations (knees, elbows, chin) Fever
Slide 29-

Neonatal Narcotic Withdrawal Syndrome Onset of manifestations: Usually within 72 hours of birth Birth to two weeks Late presentation: 2-4 weeks
Slide 30-

Neonatal Narcotic Withdrawal Syndrome Variable onset of manifestations depending on: Drug used during pregnancy Single drug versus polydrug use Dosage Timing of use before delivery Anesthesia/analgesia (labor and delivery) Fetal accumulation Delayed excretion due to tissue binding
Slide 31-

Neonatal Narcotic Withdrawal Syndrome Duration of withdrawal manifestations: 6-8 days Longer in some infants (3 – 6 months) Evaluation of abstinence/drug effects Finnegan’s Abstinence Scoring System Lipsitz modification of Finnegan Brazelton’s Neurobehavioral Assessment Scales (NBAS) NICU Network Neurobehavioral Scale (NNNS)
Slide 32-

Finnegan Scoring
Slide 33-

Finnegan Scoring
Slide 34-

Finnegan Scoring
Slide 35-

Other Scoring Systems For Narcotic Abstinence Syndrome Neonatal Brazelton Neurobehavioral Scales (NBAS) Habituation Reflexes Tone Orientation State Changes NNNS (NICHD) NICU Network Neurobehavioral Scale Similar items as NBAS Includes stress/abstinence signs Adapted for use in high-risk populations including exposed children and preterm infants
Slide 36-

Neonatal Abstinence Syndrome Severity of CNS/ANS signs: Methadone exposure: higher prevalence of seizures NAS manifestations about equally noted with maternal buprenorphine treatment Low prevalence or absence of signs in cocaine exposure Dose effect relationship (specifically tone abnormalities and cocaine exposure)
Slide 37-

Neonatal Narcotic Withdrawal Syndrome and Maternal Methadone Dashe et al: Obstet Gynecol 2002; 100:1244-9.
Slide 38-

Neonatal Abstinence Syndrome and Maternal Methadone 36 eligible; 25 studied 12 required treatment Median age of Rx: 35 hr (7-84 hrs) Median duration of Rx: 15 days (11-28 days) Mean maternal methadone dose: 47.5mg Length of stay: 20 days (14-34) Cord methadone concentration: 31ng/ml (17-70) 13 not treated Length of stay: 6 days (4-10) Mean maternal methadone dose: 65 mg Cord methadone level: 88 ng/ml (0-130) Kuschel et al: Arch Dis Child Fetal Neonatal Ed 2004; 89: F390-F393.
Slide 39-

Neonatal Abstinence Syndrome Supportive Treatment Swaddling Small frequent feedings High nutrient density formula IV fluids Decrease sensory stimulation Monitor closely for other disease status Monitor weight gain Pharmacologic treatment
Slide 40-

Narcosis Agitation NORMALITY 0 1 -3 4 -7 8 -10 11-13 14 -16 17 Abstinence Score Loss of Control Control Clinical status Intervention Very close monitoring of vital signs and state of arousal Decreased activity: developing medical problems; early signs of over sedation Intervention Point of optimal behavior and neurologic state Need for conservative measures Pharmacologic measures Need for increasing dosage STATE OF AROUSAL Modified from Finnegan, 1985 in Current Therapy in Neonatal-Perinatal Medicine Considerations When Initiating Pharmacologic Treatment
Slide 41-

Initiation of Pharmacologic Treatment Variation in threshold scores: A score greater than 7 Three scores more than 8 A score above 9 A score above 10 A score greater than 12
Slide 42-

Neonatal Narcotic Withdrawal Syndrome Pharmacologic Treatment Must be individualized Based on severity Agents: morphine, paregoric, opium, clonidine, phenobarbital, chlorpromazine, diazepam, methadone
Slide 43-

Neonatal Abstinence Syndrome (Pharmacologic Treatment) Old Drugs: Tincture of opium (10mg/mL). Contains narcotic alkaloids including codeine and morphine: concentration of morphine may vary with each administration; diluted with ethanol Paregoric or camphorated tincture of opium (contains anhydrous morphine, 0.4 mg/mL): Use declined because of potential side effects (contains isoquinolone derivative (anti-spasmodic); toxic compounds such as camphor; ethanol 44-46%, anise oil, benzoic acid, with alcohol – benzyl alcohol (severe acidosis and hypotension), glycerin (pulmonary edema).
Slide 44-

Neonatal Abstinence Syndrome (Pharmacologic Treatment) Phenobarbital: loading dose of 10 – 20mg/kg/24 hours Maintenance: 2-8mg/kg/day; taper by 10% to 20% per day. Monitor level 24-48 hours after initiation of therapy. Clonidine: non-narcotic that targets the α2 adrenergic hyperactivity; at low doses, stimulates presynaptic adrenergic receptors, thereby increasing the amount of norepinephrine released into the synapse and lowering firing rate of adrenergic neurons. 0.5 to 1.0 μg/kg initial single dose and maintenance of 3 – 5 μg/kg/day divided every 4 to 6 hours
Slide 45-

Neonatal Abstinence Syndrome (Pharmacologic Treatment) Diazepam (Valium): 1 – 2 mg/kg every 8 hours. Multiple concerns: poor sucking and increased sedation, late-onset seizures, Parenteral preparation contains benzyl alcohol and sodium benzoate which displaces bilirubin binding; contraindicated in jaundiced and preterm infants Chlorpromazine: controls CNS and GI signs; dosage of 0.55 mg/kg every 6 hours IM or PO; slow elimination with half-life of 3 days; injectable contains benzyl alcohol; other side effects: cerebellar dysfunction, decreased seizure threshold.
Slide 46-

Neonatal Narcotic Withdrawal Syndrome (Pharmacologic Treatment) Morphine: Preparation: Oral morphine solution (10mg/5 ml) with added sterile water 5ml = (1 mg/ml) or 0.1 mg in 0.1ml (expires in 7 days). Dose: 0.08 mg to 0.2 mg per dose every 3 - 4 h
Slide 47-

Neonatal Narcotic Withdrawal Syndrome (Pharmacologic Treatment) Algorithm for the UK NICU Our Current Protocol
Slide 48-

Opiate-Exposed Neonate Initiate behavioral care/intervention Decrease sensory stimulation Promote self-regulation Environmental support Swaddling; decrease vestibular movements; minimal light and sound stimulation Nutritional support (may need higher caloric density feeds)
Slide 49-

Opiate-Exposed Neonate Report of withdrawal manifestations Finnegan scoring timed with feedings (q 3 or 4 hours) 2 or 3 consecutive Finnegan scores >24 Add pharmacological treatment to behavioral intervention Morphine 0.4 mg/kg/day divide into Q 4 or Q 3 hours based on feeding schedule. Continue scoring after feedings and evaluate every 24 hours.
Slide 50-

Opiate-Exposed Neonate After 24 hours scores total >24 (3 consecutive scores) increase dose by 10% of original dose q 24 hours until stable (scores <24 total from 3 consecutive scores) If after 24 hours of initial treatment scores equal <24 total from 3 consecutive scores, continue dose for additional 48 hours; then decrease dose by 10% of maximum dose. If scores continue to be less than 24 from 3 consecutive scores for 48 hours, taper dose by 10% of maximum dose. Therefore weaning is done q 48 hours.
Slide 51-

Opiate-Exposed Neonate Weaning is done q 48 hours. If rescue needed, add half of the weaning dose (half of the 10% of maximum dose or 5%), stabilize for 48hours and use the 5% for weaning q 48 hours. If requiring greater than 1 mg/kg/day use another drug. If dose is less than 0.1 mg/kg/day, may discontinue morphine May go home on morphine if infant is going home to safe environment.
Slide 52-

Dynamics of Phenobarbital Oral loading dose 20 mg/kg Dose increase 10 mg/kg q 12 h Maintenance doses: 4 - 6 mg/kg/day Point where plasma level sufficient to control NAS Toxic plasma levels Steady state “No control” “Control” 0 40 70 80 20 Plasma concentration AGE 12 24 36 48 60 72 84 96 108 120 132 144 156 hours AVE NAS 8 10 12 9 9 8 6 5 4 Ineffective Plasma Levels
Slide 53-

N ARCAN
Slide 54-

Neonatal Abstinence Syndrome Pharmacologic Treatment Magic Butt Balm Preparation A: Desitin: 1 large tube Maalox: 30 ml Karaya powder Preparation B: Cholestyramine (QUESTRAN) 10% in Aquaphor
Slide 55-

National Survey: Management of NAS 75/102 responded 41(54.5%) have written policy on management 49 (65%) use Finnegan Scoring Only 3 use Lipsitz tool Opioid exposure: 63% use Tincture of opium or morphine Polydrug exposure: 52% Tincture of opium or morphine
Slide 56-

National Survey: Management of NAS (Opioid Exposure)
Slide 57-

National Survey: Management of NAS (Polydrug Exposure)
Slide 58-

Goals of Treatment and Management Minimize symptomatology (supportive & pharmacologic) Promote growth and weight gain Promote caretaker-child interaction Strategies directed to social issues Improve short-term and long-term outcomes Endangered children (child abuse/neglect) Long-term behavioral problems
Slide 59-

AAP Recommendations (1998) Screening should involve multiple forms, e.g., urine plus meconium NAS should be considered as a diagnosis in whom compatible signs develop; be aware of other potential diagnosis Withdrawal should be scored; consistent scoring enables consistent decisions to institute treatment and allows quantitative approach to increasing or decreasing dosing
Slide 60-

AAP Recommendations (1998) Pharmacologic therapy of seizures is indicated; other causes must be evaluated Vomiting, diarrhea, or both associated with dehydration and poor weight gain, in the absence of other diagnosis, relative indications for treatment even if absent high withdrawal scores Drug selection - match the agent causing withdrawal (opium for opioid; phenobarbital for sedative-hypnotic)
Slide 61-

AAP Recommendations (1998) Must be aware that severity of withdrawal signs has not been proven to be associated with differences in outcomes; Treatment of drug withdrawal may not alter the long-term outcome Naloxone contraindicated for opiate withdrawal
Slide 62-

Prenatal Drug Exposure: Long-term Behavior Outcome
Slide 63-

Prenatal Drug Exposure: Long-term Behavior Outcome High prenatal cocaine exposure predicts externalizing behavior from the parent and teacher’s observation Prenatal opiate exposure is associated with attention problems more evident as children are older Other predictors of behavior problems: Community violence Caretaker depression Postnatal tobacco and alcohol exposures Bada et al. Neurotoxicology Teratology 2010
Slide 64-

Breastfeeding and Maternal Drug Use AAP 2001: The Committee on Drugs strongly believes that nursing mothers should not ingest drugs of abuse, because they are hazardous to the nursing infant and to the health of the mother. However, the dose restriction for methadone was eliminated (<20 mg since 1983, as compatible with breast feeding).
Slide 65-

Methadone and Breastfeeding
Slide 66-

Methadone and Breastfeeding Amount of methadone in breast milk is very small and dependent on dose of methadone Inconclusive studies on short term and long term developmental effects of methadone received by infant Amount of methadone in breast milk may not be adequate to treat NAS
Slide 67-

Methadone and Breastfeeding Ideally women who choose to breast feed – comprehensive treatment facilities Counseling needed regarding benefits and consequences during relapse Discourage those if unstable drug recovery, have HIV, engaged in prostitution, with Hepatitis C when nipples are cracked Review relative safety of other psychotropic medications (unknown safety profiles of SSRI, antidepressants, anti-psychotic meds) Watch for overmedication post-partum (higher methadone requirement during pregnancy).
Slide 68-

Methadone and Breastfeeding (Barriers) The breastfed drug- exposed infant Challenging because of NAS; may require treatment Various complications noted in infants: Irritability State lability Hypertonicity Disorganized suck and swallow Hypersensitivity Nasal stuffiness interfering with sucking
Slide 69-

Methadone and Breastfeeding (Barriers) Other barriers to breast feeding Health care providers Treating physicians uncomfortable with safety of methadone Nursing staff uncomfortable with practice (What else may be in breast milk?)
Slide 70-

Breastfeeding and Maternal Drug Use AAP 2001: The Committee on Drugs strongly believes that nursing mothers should not ingest drugs of abuse, because they are hazardous to the nursing infant and to the health of the mother. Drugs of abuse for which adverse effects on the infant has been reported (Amphetamine, Cocaine, Heroin, Marijuana, Phencyclidine) CDC: Breastfeeding is NOT advisable if the following condition is true: The infant whose mother is using or is dependent upon an illicit drug.
Slide 71-

Summary May need universal screening for in utero drug exposure Mother will need management (address medical, drug rehabilitation, multiple social issues) Non-judgmental approach Baby will need monitoring and supportive treatment Need for pharmacologic treatment will depend on type of drug exposure and manifestations of withdrawal Promote child growth, health, and safety Direct treatment or management to child and family
Slide 72-

“The first hours and days of life are sensitive period for the mother when she is specially psychologically prepared to accept her infant as her own.”…..Lvoff et al. 2000 “The empowerment this brings may help inspire them – and us – to make the most of this sensitive window to start a new life with implications for generations to come.” ………Philipp et al. 2003